Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer

Cancer Research

Volumn 60, Issue 1, 2000, Pages 170-176

  Miyake, Hideaki ^a   Nelson, Colleen ^a,b   Rennie, Paul S ^a   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; CLUSTERIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CASTRATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CLUSTERIN; DISEASE PROGRESSION; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RNA, MESSENGER; UP-REGULATION;

EID: 0033978525     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Denis, L., and Murphy, G. P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila.), 72: 3888-3895, 1993.
2. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1220-1229, 1998.
3. Blaschuk, O., Burdzy, K., and Fritz, I. B. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem., 258: 7714-7720, 1983.
4. Rosenberg, M. E., and Silkensen, J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell. Biol., 27: 633-645, 1995.
5. Sensibar, J. A., Griswold, M. D., Sylvester, S. R., Buttyan, R., Bardin, C. W., Cheng, C. Y., Dudek, S., and Lee, C. Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinology, 128: 2091-2102, 1991.
6. Connor, J., Buttyan, R., Olsson, C. A., D'Agati, V., O'Toole, K., and Sawczuk, I. S. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int., 39: 1098-1103, 1991.
7. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res., 51: 162-166, 1991.
8. Wright, P. S., Cross-Doersen, D., Th'ng, J. P., Guo, X. W., Crissman, H. A., Bradbury, E. M., Montgomery, L. R., Thompson, F. Y., Loudy, D. E., Johnston, J. O., and Bitonti, A. J. A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp. Cell Res., 222: 54-60, 1996.
9. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation Cancer Res., 50: 3748-3753, 1990.
10. Ho, S. M., Leav, I., Ghatak, S., Merk, F., Jagannathan, V. S., and Mallery, K. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am. J. Pathol., 153: 131-139, 1998.
11. Schwochau, G. B., Nath, K. A., and Rosenberg, M. E. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int., 53: 1647-1653, 1998.
12. French, L. E., Sappino, A. P., Tschopp, J., and Schifferli, J. A. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J. Clin. Invest., 90: 1919-1925, 1992.
13. Montpetit, M. L., Lawless, K. R., and Tenniswood, M. Androgen-repressed messages in the rat ventral prostate. Prostate, 8: 25-36, 1986.
14. Sensibar, J. A., Sutkowski, D. M., Raffo, A., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., and Lee, C. Prevention of cell death induced by tumor necrosis factor a in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res., 55: 2431-2437, 1995.
15. Steinberg, J., Oyasu, R., Lang, S., Sintich, S., Rademaker, A., Lee, C., Kozlowski, J. M., and Sensibar, J. A. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res., 3: 1701-1711, 1997.
16. Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., and Lawson, D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 50: 2275-2282, 1990.
17. Gleave, M. E., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C., and Chung, L. W. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 598-1605, 1992.
18. Rennie, P. S., Bruchovsky, N., Buttyan, R., Benson, M., and Cheng, H. Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res., 48: 6309-6312, 1988.
19. Bruchovsky, N., and Rennie, P. S. Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding. Cell, 13: 272-280, 1978.
20. Gleave, M., Hsieh, J. T., Gao, C., von Eschenbach, A. C., and Chung, L. W. Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 51: 3753-3761, 1991.
21. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
22. Miyake, H., Hanada, N., Nakamura, H., Kagawa, S., Fujiwara, T., Hara, I., Eto, H., Gohji, K., Arakawa, S., Kamidono, S., and Saya, H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene, 16: 933-943, 1998.
23. Nickerson, T., Miyake, H., Gleave, M. E., and Pollak, M. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res., 59: 3392-3395, 1999.
24. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (Lond.), 371: 346-347, 1994.
25. Brandstrom, A., Westin, P., Bergh, A., Cajander, S., and Damber, J. E. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res., 54: 3594-3501, 1994.
26. He, H., Lam, M., McCormick, T. S., and Distelhorst, C. W. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J. Cell Biol., 138: 1219-1228, 1997.
27. 2+. Oncogene, 12: 2259-2266, 1996.
28. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol., 32: 329-376, 1992.
29. Saijo, Y., Perlaky, L., Wang, H., and Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res., 6: 243-249, 1994.
30. Hammad, S. M., Ranganathan, S., Loukinova, E., Twal, W. O., and Argraves, W. S. Interaction of apolipoprotein J-amyloid β-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid β-peptide. J. Biol. Chem., 272: 18644-18649, 1997.
31. Michel, D., Moyse, E., Trembleau, A., Jourdan, F., and Brun, G. Clusterin/ApoJ expression is associated with neuronal apoptosis in the olfactory mucosa of the adult mouse. J. Cell Sci., 110: 1635-1645, 1997.
32. Miyake, H., Tolcher, A., and Gleave, M. E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59: 4030-4034, 1999.
33. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2: 668-675, 1996.
34. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
35. Gleave, M., Tolcher, A., Miyake, H., Nelson, C., Brown, B., Beraldi, E., and Goldi, L. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res., 5: 2891-2898, 1999.